Department of Psychiatry, Kyung Hee University School of Medicine, Seoul 20447, Korea.
Department of Internal Medicine, School of Medicine, Korea University, Ansan 15355, Korea.
Int J Environ Res Public Health. 2021 Oct 28;18(21):11322. doi: 10.3390/ijerph182111322.
There is a paucity of published literature on the epidemiology of adult attention-deficit/hyperactivity disorder (ADHD). We investigated the time trends of the diagnostic and pharmacotherapy incidence of ADHD, including the first used medication, in the adult population based on a Korean population-based database from 2015 to 2018. The number of diagnosed cases of ADHD significantly increased from 7782 in 2015 to 17,264 in 2018 ( = 0.03), which is 0.02% to 0.04% of the total population. Similarly, the number of pharmacotherapy cases of ADHD significantly increased from 3886 in 2015 to 12,502 in 2018 ( = 0.01), which is 0.01% to 0.03% of total population. The most commonly used medication at the initiation of pharmacotherapy shifted from Penid in 2015 to Concerta in 2018. Furthermore, combination therapy with two or more drugs was the preferred method in 2016-2018. In conclusion, the identified diagnoses and pharmacotherapy incidences were very low, highlighting the need to improve the public's awareness of adult ADHD.
成人注意缺陷多动障碍（ADHD）的流行病学文献很少。我们根据韩国 2015 年至 2018 年的基于人群的数据库，调查了成人 ADHD 的诊断和药物治疗发病率的时间趋势，包括首次使用的药物。ADHD 的确诊病例数从 2015 年的 7782 例显著增加到 2018 年的 17264 例（=0.03），占总人口的 0.02%至 0.04%。同样，ADHD 的药物治疗病例数从 2015 年的 3886 例显著增加到 2018 年的 12502 例（=0.01），占总人口的 0.01%至 0.03%。药物治疗起始时最常用的药物从 2015 年的哌甲酯转变为 2018 年的专注达。此外，在 2016 年至 2018 年期间，联合使用两种或两种以上药物的治疗方法是首选。总之，确定的诊断和药物治疗发病率非常低，这突显了提高公众对成人 ADHD 认识的必要性。
